BOK Financial’s Apellis Pharmaceuticals APLS Stock Holding History

BOK Financial’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-16	Closed	-$350	–	1157
2025 Q1	$350	Hold	16	–	–	﹤0.01%	1245
2024 Q4	$439	Buy	+16	New	+$481	﹤0.01%	1248

Other funds holding APLS

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BOK Financial's APLS Position: Q2 2025 in Review

BOK Financial sold out of Apellis Pharmaceuticals (APLS) in Q2 2025, closing a stake of 16 shares — an estimated $350 sold.

BOK Financial first reported a position in APLS in Q4 2024 and held it in 2 quarters. The position peaked at $439 in Q4 2024. 247 funds tracked by Wall St. Rank hold APLS as of Q2 2025.

BOK Financial reported no remaining Apellis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
BOK Financial sold 16 Apellis Pharmaceuticals shares in Q2 2025, an estimated $350.
BOK Financial first reported a position in Apellis Pharmaceuticals in Q4 2024 and held it in 2 quarters.
BOK Financial's Apellis Pharmaceuticals position peaked at $439 in Q4 2024.
247 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2025.

Based on BOK Financial's 13F filing for Q2 2025, filed 12 Aug 2025.